8-K: Kineta Inc. Settles Dispute with RLB Holdings, Faces Nasdaq Delisting Notice

Kineta Inc. reached a settlement with RLB Holdings regarding a prior investment agreement and received a notice from Nasdaq for failing to maintain the minimum bid price.

Summary

• Kineta Inc. has entered into a settlement agreement with RLB Holdings Connecticut, LLC to resolve a dispute over a prior financing agreement.
• RLB had failed to purchase $2,500,000 of Kineta's common stock as previously agreed.
• Under the settlement, RLB will purchase $500,000 of Kineta's common stock.
• The number of shares issued will be based on the average closing price of Kineta's stock for the five days prior to the agreement plus 20% of that average.
• Kineta also received a notice from Nasdaq for not maintaining a minimum closing bid price of $1.00 per share for the last 30 consecutive business days.
• Kineta has 180 days, until October 15, 2024, to regain compliance, with a possible extension to April 13, 2025, if certain conditions are met.
• Failure to regain compliance could result in the delisting of Kineta's common stock.

Sentiment

Score: 3

Explanation: The settlement is a minor positive, but the delisting notice and the failure of the original investment agreement are significant negatives, resulting in a low sentiment score.

Positives

• The settlement with RLB Holdings ensures a $500,000 investment into the company.
• The settlement resolves potential legal claims related to the failed prior investment agreement.
• Kineta has a period of 180 days to regain compliance with Nasdaq's minimum bid price rule, with a possible extension.

Negatives

• Kineta failed to maintain the minimum $1.00 share price for 30 consecutive days, triggering a Nasdaq delisting notice.
• The company faces the risk of delisting if it cannot regain compliance with the minimum bid price requirement.
• RLB failed to fulfill its original commitment to purchase $2,500,000 of shares.

Risks

• The company's stock price may not recover sufficiently to meet Nasdaq's minimum bid price requirement.
• Delisting from Nasdaq could negatively impact the company's ability to raise capital and its stock price.
• There is no guarantee that the company will be able to regain compliance within the given time frame.

Future Outlook

Kineta intends to monitor its stock price and consider options to regain compliance with Nasdaq's minimum bid price requirement, but there is no guarantee of success.

Management Comments

• The company intends to monitor the bid price of the Companys listed securities and may, if appropriate, consider available options to regain compliance with the bid price requirement.

Industry Context

The biotech industry is known for volatile stock prices, and companies often face challenges in maintaining listing requirements. This situation is not uncommon for smaller biotech firms.

Comparison to Industry Standards

• Many small-cap biotech companies face similar challenges with maintaining Nasdaq listing requirements due to the inherent volatility of their stock prices.
• Companies like Agenus Inc. and Cellectar Biosciences have also faced delisting notices in the past, highlighting the commonality of this issue in the sector.
• The settlement agreement is a positive step for Kineta, as it secures some funding and resolves a potential legal issue, which is a common strategy for companies facing financial difficulties.

Stakeholder Impact

• Shareholders face the risk of delisting and potential loss of investment value.
• Employees may experience uncertainty due to the company's financial challenges.
• The company's ability to raise capital may be impacted by the delisting notice.

Next Steps

• Kineta needs to regain compliance with Nasdaq's minimum bid price requirement by October 15, 2024, or potentially April 13, 2025.
• The company will monitor its stock price and consider options to regain compliance.

Key Dates

Keywords

settlement agreement, Nasdaq, delisting, minimum bid price, RLB Holdings, share purchase, compliance, financing agreement